Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash flows provided by (used in) operating activities:
Net earnings	$ 18.6	$ 397.2
Adjustments to reconcile net earnings to cash provided by operating activities:
Depreciation and amortization	188.6	192.3
Share-based compensation	21.2	24.2
Non-cash Biomet merger consideration compensation expense	164.1
Income tax benefit from stock option exercises	74.0	28.8
Excess income tax benefit from stock option exercises	(9.1)	(8.6)
Inventory step-up	10.5	4.2
Gain on divestiture of assets	(18.9)
Changes in operating assets and liabilities, net of effect of acquisitions:
Income taxes	30.5	(114.4)
Receivables	(59.3)	(14.7)
Inventories	(149.9)	(85.2)
Accounts payable and accrued expenses	95.8	(1.7)
Other assets and liabilities	(87.8)	20.8
Net cash provided by operating activities	278.3	442.9
Cash flows provided by (used in) investing activities:
Additions to instruments	(104.0)	(112.0)
Additions to other property, plant and equipment	(64.8)	(63.4)
Purchases of investments	(152.6)	(783.3)
Sales of investments	398.9	691.4
Proceeds from divestiture of assets	24.1
Biomet acquisition, net of acquired cash	(7,812.9)
Investments in other assets	(9.4)	(1.4)
Net cash used in investing activities	(7,720.7)	(268.7)
Cash flows provided by (used in) financing activities:
Proceeds from senior notes	7,628.2
Proceeds from term loan	3,000.0
Redemption of senior notes	(2,740.0)
Net proceeds under revolving credit facilities	0.9	0.5
Dividends paid to stockholders	(74.7)	(70.9)
Proceeds from employee stock compensation plans	34.6	218.9
Excess income tax benefit from stock option exercises	9.1	8.6
Debt issuance costs	(58.4)	(47.7)
Repurchase of common stock		(400.5)
Net cash provided by (used in) financing activities	7,799.7	(291.1)
Effect of exchange rates on cash and cash equivalents	(16.0)	5.0
Increase (decrease) in cash and cash equivalents	341.3	(111.9)
Cash and cash equivalents, beginning of year	1,083.3	1,080.6
Cash and cash equivalents, end of period	$ 1,424.6	$ 968.7